摘要
近几年,免疫检查点抑制剂在肿瘤治疗方面取得突破性进展,随着临床应用的增多,免疫相关性不良事件(irAE)的报道也随之增多,其中免疫相关性心肌炎是一种罕见但病死率高的irAE。本文报道1例胸腺瘤患者使用Atezolizumab治疗后出现免疫相关性心肌炎,对免疫相关性心肌炎的临床特征、可能的发病机制、治疗与预后进行文献回顾。
In recent years,a breakthrough has been made in cancer treatment by immune checkpoint inhibitors(ICIs).However,with the extensive application of ICIs,reports of immune-related adverse event(irAE)associated with ICIs are increasing,among which immune-related myocarditis is rare but highly fatal.We reported a case of immune-related myocarditis after Atezolizumab treatment of thymoma,and conducted a literature review of the clinical features,possible pathogenesis,treatment and prognosis of this disease.
作者
龙浪
罗锋
王力
鄢国清
LONG Lang;LUO Feng;WANG Li;YAN Guoqing(Lung Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,China;Minda Hospital of Hubei Minzu University,Enshi 445000,China)
出处
《中国全科医学》
CAS
北大核心
2021年第14期1837-1840,共4页
Chinese General Practice
